Anti-infarct effect of magnesium is not mediated by adenosine A1 receptors in rat globally ischaemic isolated hearts

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 12, 2004, Pages 868-872

  Ebrahimi, S ^a   Faghihi, M ^a   Keshavarz, M ^a   Kadkhodaee, M ^a   Mirershadi, F ^a   Asadi, B ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adenosine; Infarction; Ischaemia; Magnesium; Reperfusion

Indexed keywords

8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; ADENOSINE A1 RECEPTOR; MAGNESIUM; TRIPHENYLTETRAZOLIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; DRUG MECHANISM; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HEART PROTECTION; HEART RATE; ISOLATED HEART; MALE; NONHUMAN; RAT;

ANIMALS; CARDIOTONIC AGENTS; MAGNESIUM; MALE; MYOCARDIAL ISCHEMIA; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A1;

EID: 11144241897     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.04128.x     Document Type: Article

References (41)

1. Shechter M, Hod H, Marks N, Behr S, Kaplinsky E, Rabinowitz B. Beneficial effect of magnesium sulfate in acute myocardial infarction. Am. J. Cardiol. 1990; 66: 271-4.
2. Noronha JL, Matuschak MG. Magnesium in critical illness; metabolism, assessment and treatment. Intensive Care Med. 2002; 28: 667-79.
3. Serebruany VL, Atar D, Delesandro MR, O'Connor CM, Gurbel PA. Changes in homeostasis after parenteral magnesium in myocardial ischemia-reperfusion: From animal studies to clinical trails. Magnes. Res. 1998; 11: 133-40.
4. Fox C, Ramsoomair D, Carter C. Magnesium: Its proven and potential clinical significance. South. Med. J. 2001; 94: 1195-201.
5. Fuchs F, Messmer K, Kuppe H, Habazetti H. Initial reperfusion with magnesium after cardioplegic arrest attenuates myocardial reperfusion injury. Thorac. Cardiovasc. Surg. 2002; 50: 208-15.
6. Headrick JP, Mckidy CJ, Willis JR. Functional and metabolic effects of extracellular magnesium in normoxic and ischemic myocardium. Am. J. Physiol. Heart Circ. Physiol. 1998; 275: H917-29.
7. Stühlinger HG. Magnesium in cardiovascular disease. J. Clin. Basic Cardiol. 2002; 5: 55-9.
8. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S. Protective role of magnesium in cardiovascular disease: A review. Mol. Cell. Biochem. 2002; 238: 163-79.
9. Rippa G, Severzellati E, Giorgi-Pierfranceschi M, Carrara GC. Magnesium and cardiovascular drugs. Interactions and therapeutic role. Ann. Ital. Med. Int. 1999; 14: 40-5.
10. Agus MS, Agus ZS. Cardiovascular action of magnesium. Crit. Care Clin. 2001; 17: 175-86.
11. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulfate in suspected acute myocardial infarction: The second Leicester Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-19.
12. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomized factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
13. Thamer V, Grunnet S, Bier F, Schlack W. Effect of magnesium on infarct size after coronary occlusion. Anim. Exp. Studies Herz 1997; 22 (Suppl. 1): 35-9.
14. Naik P, Malati T, Ratnacar KS, Naidu MU, Rajasekhar A. Cardioprotective effects of magnesium chloride in experimental acute myocardial infarction. Indian J. Exp. Biol. 1999; 37: 131-7.
15. Seelig MS, Elin RJ, Antman EM. Magnesium in acute myocardial infarction: Still an open question. Can. Cardiol. 1998; 14: 745-9.
16. Saris NE, Mervaala E, Karppanen H, Khawaja JA, Lewenstem A. Magnesium: An update on physiological, clinical and analytical aspects. Clin. Chim. Acta 2000; 294: 1-26.
17. Mallet RT, Sun J, Fan WL, Kang YH, Bünger R. Magnesium activated adenosine formation in intact perfused heart: Predominance of ecto 5-nucleutidase during hypermagnesemia. Biochem. Biophys. 1996; 1290: 165-76.
18. Sakaguchi T, Sawa Y, Kitakaze M et al. Ecto-5′ nucleotides in the cardioprotective effects of heat shock protein 72 in ischemia-reperfusion injury in rat hearts. Cardiovasc. Res. 2000; 47: 74-80.
19. Mubgwa K, Flameng W. Adenosine, adenosine receptors and myocardial protection: An updated overview. Cardiovasc. Res. 2001; 52: 25-39.
20. Hilchen T, Sommerschild HT. Preconditioning: Endogenous defense mechanisms of the heart. Acta Anaesthesiol. Scand. 2002; 46: 123-37.
21. Kitakaze M, Minamino T, Node K, Takashima S, Funaya IT. Adenosine and cardioprotection in the diseased heart. Jpn. Circ. J. 1999; 63: 231-43.
22. McCully JD, Toyoda Y, Uematsu M, Stewart RD, Levitsky S. Adenosine-enhanced ischemic preconditioning: Adenosine receptor involvement during ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2001; 280: H591-602.
23. Jonge R, Jong JW, Giacometti D, Bradamante S. Role of adenosine and glycogen in ischemic preconditioning of rat hearts. Eur. J. Pharmacol. 2001; 414: 55-62.
24. Jynge P, Falck G. High magnesium improves the postischemic recovery of cardiac function. Cardiovasc. Res. 1995; 29: 439.
25. Herzog WR, Schlossberg ML, MacMurdy KS et al. Timing of magnesium therapy affects experimental infarct size. Circulation 1995; 92: 2622-6.
26. Christensen CW, Rieder MA, Silverstein EL, Gencheff NE. Magnesium sulfate reduces myocardial infarct size when administrated before but not after coronary reperfusion in a canine model. Circulation 1995; 92: 2617-21.
27. Krause SM. Increased intracellular magnesium contributes to impairment of postischemic cardiac function. Cardiovasc. Res. 1995; 29: 438.
28. Gallagher MM, Allshire AP. Failure of magnesium to protect isolated cardiomyocytes from effects of hypoxia or metabolic poisoning. Clin. Cardiol. 2000; 23: 530-4.
29. Komori S, Li B, Matsumura K et al. Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias and reperfusion-induced arrhythmias in anesthetized rats. Mol. Cell. Biochem. 1999; 1-2: 201-8.
30. Grunert S, Ebel D, Schiack W, Thamer V. Intracoronary and intravenous magnesium does not reduce myocardial infarct size in a canine model of regional ischemia and reperfusion. J. Clin. Basic Cardiol. 2002; 5: 23-8.
31. Mutsusaka T, Hasebe N, Jin YT, Kawabe J, Kikuchi K. Magnesium reduces myocardial infarct size via enhancement of adenosine mechanism in rabbits. Cardiovasc. Res. 2002; 54: 568-75.
32. Halestrap AP. The mitochondrial permeability transition a pore way for the heart to die. J. Clin. Basic Cardiol. 2002; 5: 29-41.
33. Khalil SI. Magnesium: The forgotten cation. Int. J. Cardiol. 1999; 68: 133-5.
34. Iwai T, Tanonaka K, Inoue R, Kasahara S, Kamo N, Takeo S. Mitochondrial damage during ischemia determines postischemic contractile dysfunction in perfused rat heart. J. Mol. Cell. Cardiol. 2002; 34: 725-38.
35. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hopes CL. Mitochondrial dysfunction in cardiac disease: Ischemia-reperfusion, aging, and heart failure. J. Mol. Cell. Cardiol. 2001; 33: 1065-89.
36. Halestrap AP. The mitochondrial permeability transition: Its molecular mechanism and role in reperfusion injury. In: Brown GC, Nicholls DG, Cooper CE (eds). Mitochondria and Cell Death. Portland Press, London. 1999; 181-203.
37. Crompron M. The mitochondrial permeability transition pore and its role in cell death. Biochem. J. 1999; 641: 181-203.
38. 1 receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am. J. Physiol. Heart Circ. Physiol. 2000; 279: H2166-75.
39. Obata T. Adenosine production and its interaction with protection of ischemic and reperfusion injury of the myocardium. Life Sci. 2002; 71: 2083-103.
40. 3 agonist cardioprotection in isolated rat and rabbit hearts is blocked by the antagonist DPCPX. Am. J. Physiol. Heart Circ. Physiol. 2002; 282: H793-6.
41. Satur CMR. Magnesium and its role in cardiac surgical practice: A review. J. Clin. Basic Cardiol. 2002; 5: 67-73.